Multidrug-resistant tuberculosis
Primera línea
Linezolid is part of the first-line MDR-TB regimen (BPaL/BPaLM) per 2022: bedaquiline + pretomanid + linezolid +/- moxifloxacin for 6 months. Shortening therapy from 18-24 to 6 months is a major shift in MDR-TB management. Linezolid is started at 600 mg/day and reduced to 300 mg or interrupted for hematologic toxicity.
Therapy is prescribed and monitored by tuberculosis specialists. Peripheral and optic neuropathy are dose- and time-dependent limiters of treatment duration.
Sources